BioSpace News Archive

Ainos, Inc. today announced its unaudited financial results for the third quarter ended September 30, 2022.

Syros Pharmaceuticals today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, November 14, 2022 to report its third quarter 2022 financial results and provide a corporate update.

Repare Therapeutics Inc. today announced that members of its senior management team will participate at two investor conferences in November.

Better Therapeutics, Inc today announced it will release its third quarter 2022 financial results after the market closes on Monday, November 14, 2022.

Laborie Medical Technologies Corp, a specialist medical technology company, announced that the American Medical Association has issued the new Category 1 Current Procedural Terminology code 5X000 to report cystourethroscopy with mechanical urethral dilation and therapeutic drug delivery via coated balloon.

Vaccitech plc today announced an update to the interim analysis of safety and efficacy data from its HBV002 trial (NCT04778904).

Fate Therapeutics, Inc. announced that ONO Pharmaceutical Co., Ltd. has exercised its option to FT825/ONO-8250, a multiplexed-engineered, iPSC-derived, chimeric antigen receptor T-cell product candidate targeting human epidermal growth factor receptor 2 -expressing solid tumors.

OncoC4, Inc. announced clinical and safety data from the ongoing Phase 1/2 PRESERVE-001 trial for the part involving ONC-392 in combination with pembrolizumab in metastatic cancer.

NGM Biopharmaceuticals, Inc. announced that an abstract related to the Company’s lead myeloid reprogramming and checkpoint inhibition program, NGM707, has been accepted for presentation at the European Society for Medical Oncology Immuno-Oncology Annual Congress, which will take place December 7 – 9, 2022 at the Palexpo Exhibition Centre in Geneva, Switzerland.

Certara, Inc. announced that Arsenal Capital Partners, a private equity firm specializing in investing in and building transformational healthcare companies, has committed to make a new $449M investment in Certara.